Skip to Content
Authors Wei XD, Zhou L, Cheng L, Tian J, Jiang JJ, Maccallum J
Author Profile(s)
Journal Head Neck Volume: 31 Issue: 1 Pages: 94-101
Publish Date 2009 Jan
PubMed ID 18853445

Mounting evidence suggests that most tumors consist of a heterogeneous population of cells with a subset population that has the exclusive tumorigenic ability. They are called cancer stem cells (CSCs). CSCs can self-renew to generate additional CSCs and also differentiate to generate phenotypically diverse cancer cells with limited proliferative potential. They have been identified in a variety of tumors. In this study, we identify the marker of CSCs in the established human laryngeal tumor Hep-2 cell line in vivo. Our in vitro experiment shown as CD133, a 5-transmembrane glycoprotein expressed in Hep-2 cell line. CD133 was supposed as a candidate of CSC in laryngeal carcinoma. In this study, the expression of CD133 was detected in a Hep-2 cell line. Applying the magnetic cell sorting (MACS) technology, we reported the results of purifying CD133 positive cells from a Hep-2 cell line. Three-type cells’ tumor-forming ability was examined in vivo to identify the marker of CSCs in Hep-2 cell line.CD133 was selected as a putative marker of CSC in laryngeal carcinoma, Hep-2 cell lines. Flow cytometry was used to detect the expression of CD133 in the Hep-2 cell line. Immunomagnetic beads were applied to purify CD133-positive cells. CD133, CD133 tumor cells, and unsorted Hep-2 cells were injected into severe combined immune deficiency (SCID) mice individually to observe tumor-forming ability.Only a small proportion (3.15% /- 0.83%) of cells in the Hep-2 cell line express the CD133 marker. In comparison with CD133 tumor cells and unsorted cells, CD133() cells possess a marked capacity for tumor formation in vivo (p <.05).CD133 is 1 of the markers for CSCs in human laryngeal tumors of the Hep-2 cell line. Work on the characterization of these cells provides a powerful tool to investigate the tumorigenic process in the larynx and to develop therapies targeting the CSC. Copyright © 2016 The Board of Regents of the University of Wisconsin System